Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Cash from Operations (2016 - 2025)

Moleculin Biotech (MBRX) has 10 years of Cash from Operations data on record, last reported at 7223000.0 in Q3 2025.

  • For Q3 2025, Cash from Operations fell 18.16% year-over-year to 7223000.0; the TTM value through Sep 2025 reached 22452000.0, up 5.17%, while the annual FY2024 figure was 23862000.0, 1.15% down from the prior year.
  • Cash from Operations reached 7223000.0 in Q3 2025 per MBRX's latest filing, down from 5582000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 3600000.0 in Q1 2021 and bottomed at 8001000.0 in Q2 2022.
  • Average Cash from Operations over 5 years is 5863789.47, with a median of 5949000.0 recorded in 2024.
  • Peak YoY movement for Cash from Operations: tumbled 76.7% in 2022, then skyrocketed 35.93% in 2023.
  • A 5-year view of Cash from Operations shows it stood at 4258000.0 in 2021, then plummeted by 70.41% to 7256000.0 in 2022, then skyrocketed by 32.51% to 4897000.0 in 2023, then decreased by 3.8% to 5083000.0 in 2024, then plummeted by 42.1% to 7223000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 7223000.0 in Q3 2025, 5582000.0 in Q2 2025, and 4564000.0 in Q1 2025.